New epilepsy company on the block wins FDA approval for made-in-Korea drug to treat focal seizures
The FDA has ushered the fifth branded drug for partial-onset seizures to the market — in what its maker calls a first for the Korean biopharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
